Treating cancer by targeting the immune system.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in oncology · 2023
   Pooled it
2. Acquisition and validation of four pain subtypes of colon adenocarcinoma and prognostic analysis.Journal of anesthesia and translational medicine · 2024
   Article
3. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies.Frontiers in transplantation · 2023
   Article
4. Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer.Journal of clinical medicine · 2022
   Article
5. Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution.Journal of clinical medicine · 2021
   Article
6. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.Journal for immunotherapy of cancer · 2020
   Article
7. Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.Theranostics · 2020
   Article
8. Learning-accelerated discovery of immune-tumour interactions.Molecular systems design & engineering · 2019
   Article
9. Tumour progression and metastasis.Ecancermedicalscience · 2016
   Review
10. Are macrophages in tumors good targets for novel therapeutic approaches?Molecules and cells · 2015
    Review
11. Emerging targeted therapies for melanoma treatment (review).International journal of oncology · 2014
    Review
12. A VISTA on PD-1H.The Journal of clinical investigation · 2014
    Article
13. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.Cancer immunology, immunotherapy : CII · 2014
    Article
14. Microenvironmental regulation of tumor progression and metastasis.Nature medicine · 2013
    Review
15. Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma.Clinical, cosmetic and investigational dermatology · 2013
    Review
16. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.Future oncology (London, England) · 2013
    Review
17. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.P & T : a peer-reviewed journal for formulary management · 2012
    Article
18. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.Proceedings of the National Academy of Sciences of the United States of America · 2012
    Article
19. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Cancers · 2011
    Article
20. Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?Journal of the Royal Society of Medicine · 2011
    Article

Corrections and comments

• Comment on
  Improved survival with ipilimumab in patients with metastatic melanoma.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as